Heart Disease and Cancer Deaths — Trends and Projections in the United States, 1969–2020

1Medscape, LLC is pleased to provide online continuing medical education (CME) for this journal article, allowing clinicians the opportunity to earn CME credit.

2This activity has been planned and implemented through the joint providership of Medscape, LLC and Preventing Chronic Disease. Medscape, LLC is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

3Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

4All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at http://www.medscape.org/journal/pcd; (4) view/print certificate.

5Release date: November 17, 2016; Expiration date: November 17, 2017

6Upon completion of this activity, participants will be able to:

7Distinguish the overall effects of risk reduction and population growth and aging on the projected number of heart disease and cancer deaths to the year 2020, based on a study of mortality data, population estimates, and population projections

8Identify factors contributing to the decline in heart disease risk

9Identify factors associated with the increase in cancer risk

10EDITOR

11Rosemarie Perrin

12Editor, Preventing Chronic Disease

13Disclosure: Rosemarie Perrin has disclosed no relevant financial relationships.

14CME AUTHOR

15Laurie Barclay, MD

16Freelance writer and reviewer, Medscape, LLC

17Disclosure: Laurie Barclay, MD, has disclosed the following relevant financial relationships:

18Owns stock, stock options, or bonds from: Pfizer

19AUTHORS

20Hannah K. Weir, PhD

21Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia

22Disclosure: Hannah K. Weir, PhD, has disclosed no relevant financial relationships.

23Robert N. Anderson, PhD

24Division of Vital Statistics, National Center for Health Statistics, Centers for Disease Control and Prevention, Hyattsville, Maryland

25Disclosure: Robert N. Anderson, PhD, has disclosed no relevant financial relationships.

26Sallyann M. Coleman King, MD, MSc

27Division for Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia

28Disclosure: Sallyann M. Coleman King, MD, MSc, has disclosed no relevant financial relationships.

29Ashwini Soman, MPH

30Northrop Grumman Corporation, Atlanta, Georgia

31Disclosure: Ashwini Soman, MPH, has disclosed no relevant financial relationships.

32Trevor D. Thompson, BS

33Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia

34Disclosure: Trevor D. Thompson, BS, has disclosed no relevant financial relationships.

35Yuling Hong, MD, PhD

36Division for Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia

37Disclosure: Yuling Hong, MD, PhD, has disclosed no relevant financial relationships.

38Bjorn Moller, PhD

39Department of Registration, Cancer Registry of Norway, Oslo, Norway

40Disclosure: Bjorn Moller, PhD, has disclosed no relevant financial relationships.

41Steven Leadbetter, MS

42Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia

43Disclosure: Steven Leadbetter, MS, has disclosed no relevant financial relationships.

44For most of the last century, the leading cause of death in the United States, as measured by actual deaths, was heart disease, followed by cancer. Cancer overtook heart disease to become the leading cause of death in 1 state (Alaska) in 1993, 2 states in 2000, 8 states in 2005, and 23 states in 2010, although the trend slowed or stopped in recent years.

45The age-standardized death rate approximates the population’s risk of dying from a given cause and is used to compare risk of death between populations or within a population over time. Declining death rates indicate that the overall risk to the population of dying from heart disease or cancer decreased. However, age-standardized death rates do not convey the full extent of the burden of these diseases, because they effectively remove the influence of demographic changes related to population growth and changing age structure. Although the age-standardized death rate for heart disease began to decline in the late 1960s and for all cancers combined some 20 years later, the overall number of heart disease deaths declined and the number of cancer deaths increased.

46The number of deaths is a function of the population risk of being diagnosed and dying from that cause and the size and age structure of the population. The risk of death from heart disease and cancer generally increases with age, and over the past several decades the US population increased, particularly in the age group 65 years or older. These demographic changes are forecast to continue into this century as the cohort born after World War II, with increased longevity than earlier cohorts, enters the age groups most at risk of dying from heart disease and cancer.

47The objective of this study was to use mortality data, current population estimates, and population projections to predict age-standardized death rates and death counts for heart disease and cancer from 1969, around the peak of heart disease death rates (risk), through 2020 and to apportion changes in deaths resulting from population risk reduction, population growth, and population aging (ie, shift in age distribution toward older ages and increased longevity).

48We obtained mortality data from 1969 through 2014 from the National Vital Statistics System.The underlying cause of death was assigned according to the International Classification of Disease (ICD) in use at the time of death, converted to ICD-10 (International Classification of Disease, Revision 10), and recoded to ensure comparability over time. For these analyses, we defined heart disease as rheumatic heart disease (I00–I09), hypertensive heart disease (I11), hypertensive heart and kidney disease (I13), acute myocardial infarction (I21–I22), other ischemic or coronary heart disease (I20, I23–I25), atrial fibrillation (I48), other arrhythmias (I47, I49), heart failure (I50), and other heart disease (I26–I146, I51); we defined cancer as malignant neoplasms (ICD-10: C00–97).

49Bridged single-race population estimates based on the 2010 US Census were available through the Surveillance, Epidemiology, and End Results (SEER) Program. We obtained data on population projections of the resident population by race, age, and sex from 2015 through 2020 from the US Census Bureau’s Population Projections Program. Population estimates and projections were used as the denominators in rate calculations.

50We performed statistical analyses using SEER Stat software, version 8.3.2 (Surveillance Research Program [http://seer.cancer.gov/seerstat/]), calculating averaged, annual age-standardized death rates per 100,000 population and standardized to the 2000 population, by sex and race (all, white, black). We estimated trends in death rates from 1969 through 2014 using joinpoint regression (Joinpoint Trend Analysis Software, version 4.2.0.1, http://surveillance.cancer.gov/joinpoint/), where a maximum of 5 joined straight-line segments were fit on a logarithmic scale to the trends in annual death rates. We described the resulting trends by the slope of each line segment as the annual percentage change (APC), using t tests (2-sided, P <.05) to assess whether the APCs were significantly different from zero. We used the terms increase or decrease to describe significant trends and stable to describe nonsignificant trends.

51Methods for projecting cancer death rates and counts are described in detail elsewhere. Briefly, to project age-standardized death rates and counts for 2015 through 2020, we used Nordpred software, which uses an age-period–cohort regression model with data aggregated into six 5-year calendar periods (1985–1989, 1990–1994, 1995–1999, 2000–2004, 2005–2009, 2010–2014) and 15 age groups (15–19, 20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, ≥85 y). Separate models were constructed for heart disease causes of death and for leading cancer causes of death, by sex for all races combined. We based projections for all heart disease deaths and all cancer deaths on summed estimates among the individual disease categories. We obtained predicted death counts and age-standardized death rates by applying estimated age-specific death rates to the population projections for 2015 through 2020.

52Methods to apportion the relative contribution to changes in the total number of new heart disease or cancer deaths each year that can be attributed to changes in population risk (including changes in diagnosis and treatment practices) and demographic changes related to population size and age structure are described elsewhere. Briefly, we generated 3 sets of data for each death year from 1969 through 2020. Baseline was defined as the number of deaths from heart disease or cancer that occurred in 1969 for men and women separately. We generated one set of data for the total number of cancer deaths that would have occurred each year if the population size and age structure remained the same as it was in 1969; this set reflects the effect of changes in population risk and is similar to the age-standardized death rate. A second set of data was generated for the total number of deaths that would have occurred if the age structure had remained the same as it was in 1969; this set reflects the effect of changes in risk and population growth. A third set of data was generated for the observed number of deaths that actually occurred and thus reflects the combined impact of changes in population risk, growth, and aging. The yearly difference between each set of death counts denotes the relative contribution to the overall change in the number of deaths since 1969 attributed to population risk, growth, and aging. A decline in risk results in negative death counts, because fewer deaths are attributed to risk compared with 1969, the baseline year.

53The percentage change in death rates for heart disease declined among men (68.4%) and women (67.6%) (Table 1). By race and sex, the percentage decline was 68.8% among white men, 67.6% among white women, 59.4% among black men, and 63.8% among black women. The APCs for heart disease death rates for all races combined declined from 1969 through 2014 for men and women. By race and sex, the APC was stable in white men from 2010 through 2014 and from 2011 through 2014 for black men and women. The APC continued to decrease among white women through 2014.

54From 1969 through 2014, the overall cancer death rates declined among men (21.9%) and women (15.6%). By race and sex, the percentage change declined by 20.9% among white men, 14.5% among white women, 19.3% among black men, and 11.0% among black women. The APCs for cancer death rates increased between 1969 and 1990–1992 in men and women of both racial groups before declining in all groups beginning in the early 1990s through 2014.

55In 1969, the risk of heart disease death (measured by the ASDR) was 2.8 times higher than the risk of cancer death among white men and 2.2 times higher among black males. In 2014, the risk of heart disease death was 1.1 times higher than the risk of cancer death among black men and lower (0.9) among white women. In 2009, the cancer death rate surpassed that for heart disease among white women while actual deaths remained higher.

56Table 2 and Figure 1 show the contributions to the changes in the total observed (1969–2014) and predicted (2015–2020) number of heart disease and cancer deaths by sex and year attributed to changes in population risk, growth, and aging by sex from the baseline (1969) through 2020. Compared with 1969, the number of heart disease deaths in 2020 is predicted to decrease by 21.3% among men (–73.9% risk, 17.9% growth, 34.7% aging) and 13.4% among women (–73.3% risk, 17.1% growth, 42.8% aging). Cancer deaths are predicted to increase by 91.1% among men (–33.5% risk, 45.6% growth, 79.0% aging) and 101.1% among women (–23.8% risk, 48.8% growth, 76.0% aging). In 2017, more cancer deaths are predicted than heart disease deaths in men (321,107 vs 319,793). In 2015, similar numbers of cancers deaths (281,683) as heart disease deaths (281,675) are predicted for women.

57Figure 2 shows the observed (1969–2014) and predicted (2015–2020) number of deaths and death rates for heart disease and cancer by year for all races and both sexes combined. From 2015 to 2020, we predict the number of heart disease deaths overall to stabilize and cancer deaths to increase and surpass heart disease deaths. For 2016, we predict more deaths from cancer than from heart disease (591,426 vs 587,329). In 2020, we predict a total of 627,620 cancer deaths vs 572,415 heart disease deaths.

58Our projections indicate that cancer will soon become the leading cause of death in the United States if trends in risk of death from cancer and heart disease and population growth and aging continue. In 1969, there were more than twice as many heart disease deaths as cancer deaths. The decline in heart disease rates (risk) began earlier and was steeper than the decline in risk of death from cancer, which occurred approximately 20 years later. The magnitude of heart disease risk reduction has offset the increase in heart disease deaths from population growth and aging, while the decline in risk of cancer deaths only partially offset the increase in cancer deaths resulting from demographic changes related to population growth and aging. These findings are similar among black and white Americans.

59Several factors contributed to the decline in heart disease risk. In 1964, the first Surgeon General’s report on smoking and health linked smoking and lung cancer, and a later report linked smoking with the risk of heart attack and stroke, noting that smokers had about twice the risk of dying from heart disease than lifetime nonsmokers. Among smokers, the reduction in excess risk of death from heart disease occurs soon after cessation and is reduced by about half after only one year of smoking abstinence. After 15 years of cessation, the risk of death is slightly elevated, but similar to those who never smoked, supporting the hypothesis that the inflammatory component of cardiovascular disease is reversible. Although the declining risk of dying from heart disease has paralleled the decline in smoking prevalence, treatment of cardiovascular disease risk factors has also improved. Cohorts who were aged 50 to 60 years in the 1970s had a 43% lower 10-year cumulative mortality than similar cohorts who reached that age in the 1950s, with significant reductions in cardiovascular disease risk factors such as lower serum cholesterol levels, lower systolic blood pressure, and better overall blood pressure control. From 1980 to 2000, approximately half of the decline in heart disease death was attributed to improved treatment after acute myocardial infarction or unstable angina, secondary prevention post-myocardial infarction, treatment of heart failure, and revascularization for chronic angina. The remaining decline was attributed to further reductions in the major risk factors — total cholesterol levels, high blood pressure, and smoking — and increased physical activity. Further reduction in the risk of heart disease deaths may have been tempered by increases in body mass index and the prevalence of diabetes.

60The overall risk of death from heart disease declined in both black and white Americans and, based on our model, is predicted to continue to decline through 2020. Since 1969, the reduction in risk among men has more than offset the increase in heart disease deaths caused by population growth and aging. This reduction in risk has resulted in an overall decline in the observed number of heart disease deaths. However, we predict that the number of heart disease deaths will stabilize or increase slightly in men from 2015 to 2020 as further risk reduction is no longer able to offset the increase in heart disease deaths caused by demographic trends, particularly trends in population aging. A reduction in the number of heart disease deaths among women began more recently and is predicted to continue through 2020.

61The overall risk of dying from cancer increased throughout much of the latter part of the last century and is consistent with an increase in the incidence of 4 leading cancers: cancers of the lung and bronchus, colon and rectum, prostate, and female breast. Collectively, these cancers accounted for almost 50% of all cancer deaths in the United States. The cancer death rate began to decline in the early 1990s and was largely driven by a decline in deaths from cancers of the lung and prostate in men, breast cancer in women, and a continued decline in colorectal cancer deaths in both men and women that began in the mid-1980s. Lung cancer death rates in women began to decline in the early 2000s, approximately a decade after the decline began in men.

62The decline in lung cancer death rates in both men and women parallels a reduction in tobacco use in each group, offset by a latency period of several decades. Death rates from other tobacco-related cancers have declined as well, likely the result of reduced smoking prevalence as subsequent Surgeon General reports found convincing evidence for a direct causal relationship. Access to quality health care, including early diagnosis through screening, timely follow-up, and evidence-based treatments, is believed to have resulted in increased survival accompanied by reduced mortality from colorectal cancer and, to a lesser extent, female breast cancer and prostate cancer.

63The risk of dying from cancer increased among men and women throughout the early 1990s before declining, with further risk reduction predicted through 2020. The increase in the risk of death from cancer from 1969 to the early 1990s exacerbated the increase in cancer deaths caused by demographic changes in population growth and aging, resulting in an overall increase in the observed number of cancer deaths. As the risk of cancer deaths began to decline, the number of deaths continued to increase, although at a slower rate. Underlying these trends in deaths is the predicted number of incident cases of cancer, which is expected to increase by more than 20% from 2010 through 2020, whereas the overall risk of being diagnosed with cancer is predicted to remain stable.

64The risk of dying from heart disease and cancer generally increases with age and, as a result, the numbers of heart disease and cancer deaths increase with the growth and aging of the US population. These demographic influences are likely to continue, because the US population is expected to increase by 10% from 2010 to 2020, with the proportion of the population 65 years of age or older increasing from 13% to 16%. The reduction in risk of death from cancer started later than the reduction in risk of death from heart disease and has not been as rapid. Our models estimated that the number of deaths from cancer would surpass the number of deaths from heart disease around 2016, because heart disease deaths were predicted to stabilize or increase slightly in men, and cancer deaths were predicted to continue to increase. Heart disease deaths actually increased in 2013 and again in 2014, somewhat earlier than predicted.

65These results are subject to several limitations. This study used methods based on age–period–cohort models that identify trends in younger birth cohorts and extrapolate these trends to future older cohorts. Studies have validated these methods by using long-term cancer incidence data but not heart disease or cancer death data. These predictions are based on trends in risk during the past 10 to 30 years; trends in recent years may differ from long-term trends. As such, predictions of heart disease and cancer deaths may be overestimates, because the risk components in these models do not account for potential recent advances in primary prevention and treatment or national initiatives, such as CDC’s Screen for Life: National Colorectal Cancer Action Campaign (http://www.cdc.gov/cancer/colorectal/sfl/) or the Million Hearts project (http://millionhearts.hhs.gov/). At the same time, our predictions may be underestimates because the risk component may not fully account for the potential effect of increased prevalence of obesity and diabetes on risk for cardiovascular disease or for cancers such as pancreatic cancer, which is increasing and now is the fourth leading cause of cancer-related deaths in the United States.

66The population projections used in these predictions are themselves forecasts of the population size and age composition based on assumptions on future births, deaths, and migration. Furthermore, overall life expectancy in the United States is improving even as disparities by race and socioeconomic factors are increasing; these trends are likely to affect population projections. Possible misclassification of underlying cause of death may contribute to imprecision in our estimates.

67To counter the anticipated growth in the number of heart disease and cancer deaths, increase the health span of an aging population, and reduce the incidence of heart disease and cancer, a greater emphasis on primary prevention and improved treatment is needed. CDC estimates that each year approximately 91,000 premature deaths from heart disease and 84,000 premature deaths from cancer are potentially preventable. Heart disease and cancer share numerous related risk factors, including tobacco use, obesity, and physical inactivity. Further reductions in deaths might yet be achievable if Healthy People 2020 objectives related to risk factors, early diagnosis, and access to health care are met.